- Home
- CB vs SNY Comparison
CB vs SNY Comparison
Compare CB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | SNY |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | Switzerland | France |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.5B | 119.4B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | CB | SNY |
|---|---|---|
| Price | $329.55 | $48.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $316.88 | $61.50 |
| AVG Volume (30 Days) | 1.6M | ★ 3.8M |
| Earning Date | 02-03-2026 | 01-29-2026 |
| Dividend Yield | 1.24% | ★ 3.37% |
| EPS Growth | N/A | ★ 44.16 |
| EPS | ★ 23.94 | 7.52 |
| Revenue | ★ $58,842,000,000.00 | $54,850,299,422.00 |
| Revenue This Year | N/A | $2.70 |
| Revenue Next Year | $4.65 | $6.84 |
| P/E Ratio | $13.09 | ★ $12.62 |
| Revenue Growth | ★ 7.43 | 5.49 |
| 52 Week Low | $263.14 | $44.62 |
| 52 Week High | $316.94 | $60.12 |
Technical Indicators
Market Signals| Indicator | CB | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 77.13 | 53.95 |
| Support Level | $299.09 | $47.20 |
| Resistance Level | $305.75 | $47.89 |
| Average True Range (ATR) | 5.65 | 0.73 |
| MACD | 2.19 | 0.17 |
| Stochastic Oscillator | 88.38 | 83.58 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.